# NuCana plc: overview NCNA · Nasdaq · CIK 1709626 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ncna.md) · [Financials](/companies/ncna/financials.md) · [Filings](/companies/ncna/filings.md) · [Insiders](/companies/ncna/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.78)](/filings/0000950170-24-034208.md) | [(0.61)](/filings/0000950170-25-042709.md) | [(0.53)](/filings/0001193125-26-116030.md) | [(0.26)](/filings/0001193125-26-116030.md) | [0.00](/filings/0001193125-26-116030.md) | | Free cash flow | $m | [(23.9)](/filings/0000950170-24-034208.md) | [(23.2)](/filings/0000950170-25-042709.md) | [(26.4)](/filings/0001193125-26-116030.md) | [(19.1)](/filings/0001193125-26-116030.md) | [(7.5)](/filings/0001193125-26-116030.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ncna/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $71.5k | 47,043 | | New +47,043 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $41.2k | 27,099 | | Added +13,244 | | [Glass Jacobson Investment Advisors llc](/funds/1964394.md) | 2026-06-30 | $22.8k | 15,000 | | Unchanged | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $7.1k | 4,698 | | Added +976 | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $286 | 188 | | New +188 | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $286 | 188 | | New +188 | | [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $25 | 16,870 | | New +16,870 | | [Caitong International Asset Management Co., Ltd](/funds/1963355.md) | 2026-06-30 | $8 | 5 | | Added +3 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $3 | 2 | | Unchanged | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $2 | 1 | | New +1 | ## Recent filings [All 275 filings](/companies/ncna/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 04:09 ET | [6-K](/filings/0001193125-26-408365.md) | Report of a foreign private issuer, period 2026-09-30 | 0001193125-26-408365 | | 2026-08-13 | 16:17 ET | [6-K](/filings/0001193125-26-349254.md) | Report of a foreign private issuer, period 2026-06-30 | 0001193125-26-349254 | | 2026-06-08 | 07:52 ET | [6-K](/filings/0001193125-26-260703.md) | Report of a foreign private issuer, period 2026-06-08 | 0001193125-26-260703 | | 2026-06-01 | 08:12 ET | [6-K](/filings/0001193125-26-249817.md) | Report of a foreign private issuer, period 2026-06-01 | 0001193125-26-249817 | | 2026-05-14 | 16:44 ET | [6-K](/filings/0001193125-26-224224.md) | Report of a foreign private issuer, period 2026-05-14 | 0001193125-26-224224 | | 2026-05-06 | 16:07 ET | [6-K](/filings/0001193125-26-208951.md) | Report of a foreign private issuer, period 2026-05-06 | 0001193125-26-208951 | | 2026-03-19 | 16:23 ET | [20-F](/filings/0001193125-26-116030.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001193125-26-116030 | | 2026-03-19 | 16:07 ET | [6-K](/filings/0001193125-26-115968.md) | Report of a foreign private issuer, period 2026-03-19 | 0001193125-26-115968 | | 2026-03-18 | 18:39 ET | [SCHEDULE 13D](/filings/0001193125-26-114552.md) | Ownership report, active investor | 0001193125-26-114552 | | 2026-01-06 | 08:11 ET | [6-K](/filings/0001193125-26-003489.md) | Report of a foreign private issuer, period 2026-01-06 | 0001193125-26-003489 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-116030.md), filed Mar 19, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1709626 - Tickers: NCNA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: X0 - Filer category: Non-accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.